2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - New Orleans Theatre C
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

516 Pembrolizumab plus brentuximab vedotin in relapsed/refractory cutaneous T-cell lymphoma: Interim results of a Phase 2 trial

Tarsheen Sethi, MD, Ondrej Blaha, PhD2, Francesca Montanari, MD3, Arjun Ravishankar, MBBS4, Kacie Carlson, PA5, Julie Lecco6, Mina L Xu, MD7, Stephanie Halene, MD8, Michael Girardi, MD, FAAD9, Francine Foss, MD10, David C Fisher, MD11
1 Yale University School of Medicine, New Haven, Connecticut, United States
2 Yale University School of Medicine, New Haven, Connecticut, United States
3 Yale University School of Medicine, New Haven, Connecticut, United States
4 Yale University School of Medicine, New Haven, Connecticut, United States
5 Yale University School of Medicine, New Haven, Connecticut, United States
6 Yale University School of Medicine, New Haven, Connecticut, United States
7 Yale University School of Medicine, New Haven, Connecticut, United States
8 Yale University School of Medicine, New Haven, Connecticut, United States
9 Yale University School of Medicine, New Haven, Connecticut, United States
10 Yale University School of Medicine, New Haven, Connecticut, United States
11 Dana Farber Cancer Institute, Boston, Massachusetts, United States

Background: Mycosis fungoides (MF) and Sézary syndrome (SS), collectively cutaneous T-cell lymphoma (CTCL), are incurable T-cell malignancies with poor outcomes in advanced and/or multiply relapsed disease. Brentuximab vedotin (BV) has established CTCL activity and may promote immunogenic cell death, allowing potential synergy with PD-1 blockade that restores exhausted antitumor T-cell function. We report a prespecified CTCL subgroup interim analysis of an ongoing phase 2 trial of BV plus pembrolizumab in CD30-positive relapsed/refractory (R/R) T-cell lymphoma (NCT05313243).

Methods: This single-arm, open-label, multicenter trial used a Simon optimal two-stage design and enrolled adults with R/R CD30-positive (defined as CD30 ≥ 1%) T-cell lymphomas including CTCL after ≥ 1 prior systemic therapy, ECOG performance status (PS) 0-1, and adequate organ function. BV 1.8 mg/kg was given intravenously (IV) on day 1 of 21-day cycle for up to 16 cycles; pembrolizumab 200 mg was given IV on day 3 of cycle 1 and day 1 of cycles 2-35. Response was assessed after 3 cycles and at protocol-defined intervals using global response score for CTCL. The primary endpoint was objective response rate (ORR) after 3 cycles. Secondary endpoints included best response, response timing, response duration, progression-free survival (PFS), overall survival (OS), and CTCAE v5 safety. Exact 95% confidence intervals (CIs) were calculated for response proportions, and time-to-event endpoints used Kaplan-Meier methods. Treatment-emergent adverse events (TEAEs) were adverse events occurring during the treatment-emergent period regardless of causal attribution. Treatment-related AEs were those attributed to BV or pembrolizumab.

Results: Of the 15 screened CTCL patients, 14 received study treatment. Median age was 70.5 years (range, 26.8–82.4), 10/14 (71.4%) were male, and ECOG PS was 0 in 8 (57.1%) and 1 in 6 (42.9%) patients. Baseline nodal and blood involvement were recorded in 5 (35.7%), and 3 (21.4%) patients, respectively. The cohort included 8 stage IB (57.1%),4 stage IIB (28.6%), and 2 stage IVA1 (14.3%) patients with a median 2.5 (IQR 2-4; range 1-14) prior lines of systemic therapy. Baseline modified Severity Weighted Assessment Tool (mSWAT) was available for all 14 patients (median 57.9, range 32–138). Median BV and pembrolizumab administrations were 4.5 (range, 1-11) and 5 (range, 1-34), respectively.  At the first response assessment, global responses were: CR in 2, PR in 2, SD in 6, PD in 3, and not evaluable (NE) in 1 patient, yielding an ITT ORR of 28.6% (4/14; 95% CI: 8.4%-58.1%) and disease-control rate (DCR) of 71.4% (10/14; 95% CI: 41.9%-91.6%). Best global responses were CR in 3, PR in 4, SD in 3, PD in 3, and NE in 1. Best ORR was 50.0% (7/14; 95% CI: 23.0%-77.0%), CR rate was 21.4% (3/14; 95% CI: 4.7%-50.8%), and DCR was 71.4% (10/14; 95% CI: 41.9%-91.6%). Serial mSWAT data were evaluable in 11 patients: 3 achieved CR, 3 PR, 3 SD, and 2 PD, for a skin ORR of 54.5% (6/11; 95% CI: 23.4%-83.3%) and CR rate of 27.3% (3/11; 95% CI: 6.0%-61.0%). Among the 7 global responders, median time to response was 2.5 months (mths) (95% CI: 2.1–4.1) and median response duration was not reached (NR) (95% CI, 3.9–NR) at a median response follow-up of 12 mths. At a median follow-up of 19.7 mths (range, 4.7–28.8), median OS was NR, and 12-month OS was 92.3% (95% CI: 56.6–98.9). Median PFS was 4.2 mths (95% CI, 2.7-NR) and 12-month PFS was 39.6% (95% CI: 12.8%-65.8%).

TEAEs occurred in 12/14 patients (85.7%), including 10/14 (71.4%) treatment-related AEs. Grade ≥3 treatment-related AEs occurred in 3/14 patients (21.4%), including decreased WBC count, decreased neutrophil count, fatigue, peripheral sensory neuropathy, and maculopapular rash. Most common treatment-related AEs were fatigue (6), increased AST (6), increased ALT (5), nausea (5), and peripheral sensory neuropathy (4). No treatment-related serious adverse events (SAEs) or deaths occurred and there were no reported cases of hyper progression.

Conclusions: In this prospective CTCL cohort, BV plus pembrolizumab produced a best global ORR of 50.0%, including a 21.4% CR rate, with concordant, clinically meaningful skin activity. Responses deepened after the first assessment in a subset of patients. Toxicity was manageable with grade ≥3 treatment-related AEs in 21.4% and no treatment-related SAEs or deaths. These findings support continued evaluation of this combination therapy in R/R CTCL.

 

Tarsheen Sethi, MD: MERCK - Research Funding; KYOWA KIRIN - Research Funding